<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589288</url>
  </required_header>
  <id_info>
    <org_study_id>IOGPGC09</org_study_id>
    <nct_id>NCT02589288</nct_id>
  </id_info>
  <brief_title>Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus</brief_title>
  <official_title>Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus For Postoperative Analgesia After Day-Case Anterior Cruciate Ligament Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASST Gaetano Pini-CTO</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASST Gaetano Pini-CTO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized , blinded study is to compare two different infusion
      techniques (continuous VS intermittent automatic bolus) to assess the effects of
      postoperative analgesia after Day-Case anterior cruciate ligament (ACL) reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS Score</measure>
    <time_frame>72h postoperative</time_frame>
    <description>Evaluation of numeric rating score (NRS) in patient with automatic intermittent bolus of Ropivacaine 0,2% instead of classic continuous perfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Up and Go test</measure>
    <time_frame>72h postoperative</time_frame>
    <description>&quot;up and go&quot; test: time need to get up from a chair, walk for 3 meters, and come back to seat down on the chair</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioids request</measure>
    <time_frame>72h postoperative</time_frame>
    <description>Opioids consumption will be recorded throughout 72 postoperative hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local anesthetic consumption</measure>
    <time_frame>72h postoperative</time_frame>
    <description>Evaluation of local anesthesia consumption every 6h in first 72 postoperative hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10mt walk test</measure>
    <time_frame>72h postoperative</time_frame>
    <description>time need to walk 10 meters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Injury of Anterior Cruciate Ligament</condition>
  <arm_group>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Automatic Intermittent Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Infusion of ropivacaine 0.2%</intervention_name>
    <description>Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).</description>
    <arm_group_label>Continuous Infusion</arm_group_label>
    <other_name>naropine 0.2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Automatic Intermittent Bolus of ropivacaine 0.2%</intervention_name>
    <description>Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).</description>
    <arm_group_label>Automatic Intermittent Bolus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years old

          -  American society of anesthesiology (ASA) physical status I-II

          -  Signed informed consensus

        Exclusion Criteria:

          -  ASA &gt;II

          -  Unstable neurological disease

          -  Diabetic mellitus (DM) type I-II

          -  Allergy to used drugs

          -  Opioid chronic treatment

          -  Consensus refusal or not valid

          -  Anticoagulant therapy

          -  Postoperative intensive care required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianluca Cappelleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianluca Cappelleri, MD</last_name>
    <phone>+390258296297</phone>
    <email>gianluca.cappelleri@gpini.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto ortopedico Gaetano Pini</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Cappelleri, M.D.</last_name>
      <phone>+390258296297</phone>
      <email>gianluca.cappelleri@gpini.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 19, 2016</lastchanged_date>
  <firstreceived_date>October 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASST Gaetano Pini-CTO</investigator_affiliation>
    <investigator_full_name>Gianluca Cappelleri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
